Aspirin for secondary prevention of cardiovascular disease

RA Byrne, R Colleran - The Lancet, 2020 - thelancet.com
The antithrombotic efficacy of low-dose aspirin is well established. Its primary clinical effect
is mediated by inhibition of platelet cyclooxygenase-1, which reduces thromboxane A2 …
被引用次数：16 相关文章
[PDF] cvridublin.ie

[PDF][PDF] Aspirin for secondary prevention of cardiovascular disease

D Mitchell - cvridublin.ie
The antithrombotic efficacy of low-dose aspirin is well established. Its primary clinical effect
is mediated by inhibition of platelet cyclooxygenase-1, which reduces thromboxane A2 …
[PDF] taraproject.eu

[PDF][PDF] Aspirin for secondary prevention of cardiovascular disease

D Mitchell - taraproject.eu
The antithrombotic efficacy of low-dose aspirin is well established. Its primary clinical effect
is mediated by inhibition of platelet cyclooxygenase-1, which reduces thromboxane A2 …
[PDF] taraproject.eu

[PDF][PDF] Aspirin for secondary prevention of cardiovascular disease

D Mitchell - taraproject.eu
The antithrombotic efficacy of low-dose aspirin is well established. Its primary clinical effect
is mediated by inhibition of platelet cyclooxygenase-1, which reduces thromboxane A2 …

Aspirin for secondary prevention of cardiovascular disease

RA Byrne, R Colleran - Lancet (London, England), 2020 - pubmed.ncbi.nlm.nih.gov
Aspirin for secondary prevention of cardiovascular disease Aspirin for secondary prevention
of cardiovascular disease Lancet. 2020 May 9;395(10235):1462-1463. doi: 10.1016/S0140-6736(20)30799-6 …